Large Trial Validates Detection of ARV7 Biomarker Using Epic Sciences Platform to Predict Treatment Outcomes for Prostate Cancer Patients

Large Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences’ Platform to Predict Treatment Outcomes for Prostate Cancer Patients

14:10 EDT 14 Mar 2019 | Speciality Pharma Journal

SAN DIEGO, March 13, 2019 /PRNewswire/ — Epic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (androgen receptor splice variant-7) as a predictor of resistance to anti-androgen therapy in men with metastatic castration-resistant prostate cancer (mCRPC). Data from the PROPHECY trial, published in the Journal …

More From BioPortfolio on "Large Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences’ Platform to Predict Treatment Outcomes for Prostate Cancer Patients"